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Abstract: 
Purpose of the review: A significant increase in the number, type, and availability of 
new psychoactive substances (NPS) with dissociative and psychedelic potential has 
occurred worldwide over the last few decades. Psychedelic substances have historically 
been used in order to achieve altered states of consciousness such as dissociative states. 
We aimed here at describing both the large number of novel ketamine-like dissociatives 
and tryptamine/lysergamide/phenethylamine psychedelics available, whilst describing 
the acute/long term clinical scenarios most commonly associated with their intake.  
Recent findings: An updated overview of the clinical and clinical pharmacological 
issues related to some of the most popular NPS categories has been provided, describing 
both psychosis and remaining psychopathological issues related to them.  
Conclusions: Although the complex link between NPS and psychiatric illnesses is yet 
to be fully understood, NPS misuse is now a significant clinical issue and an increasing 
challenge for clinicians working in both mental health and emergency departments. 
 
 
Introduction  
The growing epidemic of addiction to both classic and new psychoactive substances 
(NPS) has become a reason of significant concern [1]. The latest published statistics 
from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) show 
that the number of NPS notified to the agency was over 670 by the end of 2017; 632 of 
these substances were notified after 2004 [1]. Of this latter total, 179 were synthetic 
cannabinoids, 127 synthetic cathinones; 77 phenethylamines; 38 synthetic opioids; 35 
arylalkylamines; 27 tryptamines; and 23 benzodiazepines. Given the globalised nature 
of the market, NPS can pose serious cross-border threats to public health as well as an 
increasing challenge for mental health practitioners [1]. In fact, large levels of 
availability of NPS with dissociative and psychedelic potential have been identified 
worldwide [2].  
In this context, one might wonder which are the issues explaining attraction towards 
both psychedelics and dissociatives. According to Jaffe [3], those who self-administer 
with these molecules try to experiment with: ‘…states of altered perception, thought, 
and feeling that are not experienced otherwise, except in dreams or at times of religious 
exaltation…’. Hence, one could argue that for dissociatives and psychedelics 
enthusiasts the positive reinforcement can revolve around escape from the ego and/or a 
frustrating environment. Moreover, in this self-medication perspective, the chemical 
experience may be seen by the users as helpful to overcome depressive or pre-psychotic 
states of mind [4•]. At times, this drug intake may help the subject to identify new 
meanings (e.g. relating to the creation of the universe; the mathematical order of the 
systems of nature; the meaning of life; etc.) of currently perceived bizarre/pathological 
experiences, however creating more psychological imbalance [5]. This understanding 
of ‘novel meanings’ may, in turn, reinforce the mood and the creative dimension of the 
user [6-7]. According to some Authors, these positive effects of psychedelics have 
opened up the possibility of the use of some selected substances for therapeutic 
purposes [8].  
 
Dissociation and the psychedelic/hallucinogenic experience  
The contemporary definition of ‘dissociation’ bears similarities with the concept of 
‘Splitting’ or ‘Spaltung’, e.g. the lack of associations between thoughts, emotions, 
attitudes and acting [9-11]. Over the last century or so, the term dissociation has been 
associated with a range of different meanings, including [12]: a) a peculiar and complex 
personality organization; b) a defense mechanism, from the psychoanalytical 
perspective; c) a process which characterizes the initial splitting/division of the 
personality following a traumatic event; d) a broad set of experiences and symptoms 
that are characterized by the breakdown of integrated psychological functioning. More 
recently, with the fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) [13], ‘dissociation’ has been related to the ‘disruption of and/or 
discontinuity in the normal integration of consciousness, memory, identity, emotion, 
perception, body representation, motor control, and behaviour….’, and includes 
clinical elements such as amnesia, depersonalisation, derealisation, identity confusion, 
and identity alteration. DSM-5 dissociative disorders include: the dissociative identity 
disorder; the dissociative amnesia; and the depersonalization/derealization disorders.  
At a Trans-diagnostic level, the experience of dissociative symptoms has been linked 
to the occurrence of acute stress and/or traumatic events [14••]. On a 
cognitive/emotional level, dissociation may be a learned automatic response to reduce 
or avoid aversive emotional states [14••]. 
Per se, dissociation can be either a pleasant or an unpleasant experience. Historically, 
human beings have researched a range of methods to reach, typically with plants or 
herbs, pleasant states of dissociation from reality [15-16]. More recently, with the 
identification of the semi-synthetic, strongly psychedelic, LSD molecule, the modern 
era of the psychedelic culture has started [17-18].  
The label ‘dissociative’ was initially related to the peculiar state of consciousness 
generated by the uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist 
ketamine [19]. Typically, dissociative molecules are those altering perceptions of sound 
and sight, and also generating feelings of detachment from reality, with these mind-
altering effects which not generally being conceived as proper hallucinations [20]. 
Dissociatives include phencyclidine (PCP), ketamine, and a range of derivatives [21-
24•]. 
Conversely, psychedelic/hallucinogen experiences typically include thought and 
visual/auditory changes, or altered states of consciousness. Most hallucinogens can be 
roughly divided into tryptamines, lysergamides and phenethylamines [20; 25-26•].  
 
Aims 
In this study, we aimed at: (a) identifying and describing the large number of 
psychedelic and dissociative NPS available; and (b) describing the acute/long term 
clinical scenarios most commonly associated with the intake of a range of NPS, 
including: new/novel psychedelics and ketamine-like dissociatives. 
 
Methods 
We searched Medline/PubMed to identify studies using the terms ‘new psychoactive 
substances,’ ‘NPS,’ ‘legal highs,’ ‘designer drugs,’ ‘research chemicals,’ ‘emerging 
drugs of abuse,’ ‘emerging drugs of misuse,’ ‘dissociatives,’ ‘ketamine-like drugs,’ 
‘hallucinogenic drugs,’ ‘psychedelics’, and ‘psychopathological consequences’. The 
search was filtered by ‘English and human’. Further references were retrieved from 
national/international agencies’ reports.  
 
The tryptamine and lysergamide psychedelic/hallucinogenic NPS 
New/novel psychedelics include a vast range of molecules associated with 
hallucinogenic effects, but at times also possessing stimulant and/or entactogenic 
properties. The common issue in the pharmacology of hallucinogenic drugs is agonism 
or partial agonism of 5-HT2 serotonin receptors, particularly 5-HT2A and/or other 5-
HT2 receptors [20; 27], although further neurotransmitters’ pathways may be involved 
as well. For example, the naturally occurring tryptamine ibogaine interacts strongly 
with the NMDA receptor, σ–receptors, μ-opioid receptors, and muscarinic receptors, 
apart from causing serotonin and dopamine reuptake inhibition at their transporters 
[20]. Hence, the different hallucinogenic drugs may have different levels of potency, 
effects, duration, and risks.  
 
The tryptamine psychedelics 
Tryptamines are a group of monoamine alkaloids, very similar to the endogenous 
neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Apart from their agonism at 
5-HT1A, 5-HT2A and 5-HT2C, the vesicular monoamine transporter 2 (VMAT2), σ-
1, serotonin transporter (SERT) and traceamine-associated (TAR) receptors are also 
involved [28••]. Novel tryptamines, available as capsules, tablets, powder, or liquid 
formulations, include: 5-MeO-AMT (5-methoxy-α-methyltryptamine), made available 
as an LSD alternative and presenting with a range of sympathomimetic effects; 5-MeO-
DALT (N-diallyl-5-methoxy-tryptamine); 4-HO-DALT (N,N-diallyl-4-
hydroxytryptamine); 5-MeO-DIPT (5-methoxy-diisopropyltryptamine-aka ‘foxy’ or 
‘foxy methoxy’), which is structurally related to dimethyltryptamine/DMT and 
bufotenin; DET (N,N-diethyltryptamine), significantly inhibiting monoamine oxidase 
and producing hallucinogenic effects similar to DMT or mescaline; 5-IT (5-(2-
aminopropyl)indole); and 5-MeO-DMT (5-methoxy- N, N-dimethyltryptamine) [28••-
29].  
The predominant clinical effects of tryptamines consist in visual hallucinations, 
alterations in sensory perception, distortion of body image, depersonalization, marked 
mood lability and anxiety/panic. Untoward effects include agitation, tachyarrhythmia 
and hyperpyrexia. DMT, in particular, produces strong hallucinogenic LSD-like 
effects, powerful entheogenic experiences/intense visual hallucinations, and euphoria. 
Since DMT is inactive after oral administration, unless combined with Monoamine 
Oxidase Inhibitors (MAOis, e.g. like in Ayahuasca), it is usually injected, snorted, or 
smoked. There are small numbers of confirmed post-mortem toxicology reports on 
tryptamines. Some hallucinogens like αMT (α-methyltryptamine) and AET (α-
ethyltryptamine) have strong stimulant effects.  
 
Tryptamines in nature: Some tryptamines are naturally found, i.e. in Delosperma 
species plants (dimethyltryptamine, DMT; 5-MeO-DMT/5-methoxy-
n,ndimethyltryptamine); and in amphibians (bufotenin), whilst 5-hydroxy-
indolethylamines are common constituents of venoms of the genre Hyla, 
Leptodactylus, Rana, and Bufo alvarius [5; 25]. DMT has also been found in other plant 
sources, e.g. Phalaris arundinacea and Mimosa hostilis [28••].  
Most popular psychedelic fungi include psilocybin mushrooms, which contain 
psilocybin and psilocin; their hallucinogenic effects occur within the first 2 h after oral 
intake and last up to 4–8 h. Psilocin is a partial 5-HT2A agonist, with little 
dopaminergic or noradrenergic activity [28••]. These mushrooms, known as 
‘teonanacatl’, meaning ‘God’s flesh’ [30-31] were used by the Aztec shamans, but also 
in Australia and in Eastern Tanzania [32], in healing ceremonies and in a variety of 
religious and divinatory rituals. Turton et al. [33] described the subjective experience 
of intravenous psilocybin, which included altered somatosensory, visual, auditory, and 
proprioceptive sensations, perceptual changes, and a variety of effects on cognition, 
mood, memory, and spiritual or mystical experiences. Psilocybin-induced visual 
perceptual alterations may include complex visual hallucinations of scenes and 
pictures, visual elementary hallucinations of regular patterns, colours, light, and light 
flashes [34]. In another study [35], psilocybin induced profound changes in mood, 
perception, and thought, with most subjects having described the experience as 
pleasurable, enriching, and non-threatening. However, at the highest dosages 
administered, strong dysphoria and/or anxiety/panic were reported. Psilocybin has 
frequently been reported to cause transient headache [36]. A case of a severe 
rhabdomyolysis and acute renal failure after Psilocybe mushroom ingestion has been 
reported as well, followed by encephalopathy with cortical blindness and eventual 
recovery over several months [37].  
Peyote (Lophophora williamsii) is a small cactus native to the American Southwest and 
Northern Mexico that has been used for millennia and is consumed as a sacrament 
during services of the Native American Church [38-39]. It contains the psychedelic 
compound mescaline, which is also found in the San Pedro and Peruvian Torch cacti. 
Halpern and colleagues [40] compared 61 Navajo Native American Church members 
who regularly ingested peyote with 79 individuals reporting minimal use of peyote, 
alcohol, or other substances. For the peyote-using group, total lifetime peyote exposure 
was not associated with neuropsychological performance. By contrast, recreational use 
of peyote has led to adverse events, including one case of a prolonged (2 weeks) peyote-
induced psychosis [41].  
Ayahuasca, also known as yagé or hoasca, is a decoction prepared from a mixture of 
two plants: the pounded bark from Banisteriopsis caapi vines and leaves from 
Psychotria viridis. The latter contains the hallucinogen DMT. Its use has been 
incorporated as a sacrament into the religious practices of two syncretic Brazilian 
churches; União do Vegetal (UDV) and the Santo Daime. Ayahuasca has a long history 
of use by natives in the Amazon valley of South America [31; 42]. Bouso and 
colleagues [43•] found that ayahuasca users who were members of the UDV Brazilian 
did not show psychopathology or worse neuropsychological performance in 
comparison with non-users, and this was consistent with findings reported earlier by 
Grob and colleagues [44]. De Araujo and colleagues [45] speculated that the robust 
visions induced by ayahuasca may be initiated in the primary visual cortex. 
 
The lysergamide/LSD-like psychedelics 
LSD and other lysergamides share a complex molecular structure with both tryptamine 
and phenethylamine backbones. However, lysergamide structures are sufficiently 
elaborated from these skeletons for them to be more usefully considered a distinct class 
of hallucinogenics [20].  
In the recreational drug scenario, LSD appears as a crystalline powder soluble in water 
which is made available as sugar cubes or small squares of papers/stamps meant to be 
typically ingested. Its effects are rapid and include headache, raised pulse rate, dilated 
pupils, nausea, blood pressure alterations, and sometimes increase in body temperature. 
Its effects may vary according to both the subject expectation/mood and the setting, and 
typically include: idiosyncratic perceptual disturbances such as stationary objects 
appearing to move and changing shape, synesthesia, distortions of body image, and 
perception of time [28••]. Tolerance, dependence, and withdrawal experiences have 
been described by users. Adverse effects may include ‘bad trips,’ that is an unpleasant, 
often terrifying, post-intake drug experience. Spontaneous recurrence of the drug-
induced experience (i.e. flashbacks) is fairly common after LSD use [28••].  
In a recent study by Schmid et al. [46], 200 micrograms of LSD produced a pronounced 
alteration in waking consciousness that lasted for 12 hours and included visual 
hallucinations, audio-visual synesthesia, and derealization/depersonalization 
experiences. Compared with placebo, LSD increased closeness to others, openness, and 
trust; all effects subsided completely within 72 hours. In other studies, LSD was found 
to increase suggestibility [47-50] and enhance music-evoked emotion [51]. Although 
the association between lifetime use of psychedelics and mental health is a reason of 
current debate [52], LSD use has been associated to potentially life-threatening 
consequences, including rhabdomyolysis [53]; vascular ischaemia related to a single 
ingestion [54]; and cortical blindness [55].  
Some novel LSD derivatives have recently reached the market, such as LSZ (lysergic 
acid 2,4-dimethylazetidide), 1-P-LSD (1-propionyl-D-lysergic acid diethylamide 
hemitartrate), ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide), PRO-LAD (6-
propyl-6-nor-lysergic acid diethylamide), and AL-LAD (6-allyl-6-nor-lysergic acid 
diethylamide). They produce effects resembling those of LSD, having similar 
pharmacological action at 5-HT2A receptors, but possessing different potencies, kick-
off effects and duration [28••]. 
Lysergamides may be found in nature: e.g. LSA naturally occurs in the seeds of both 
Argyreia nervosa and Ipomoea violacea (for a thorough review, see [56•].  
 
The phenethylamine psychedelics 
Phenethylamines are synthetic compounds available in tablets, capsules, 
powder/crystal. They act on serotoninergic receptors, leading to psychedelic effects, 
and some of them inhibiting the monoamine reuptake as well. Because of its stimulant 
effects, 3,4-methylenedioxy-methamphetamine (MDMA, ‘ecstasy’) is one of the most 
popular drugs among young and party people. Recently, a growing use of new powerful 
molecules, such as the ‘2C’ and ‘D’ series; the benzodifurans; and others (e.g., 4-
methylthioamphetamine/4-MTA; and 6-(2-aminopropyl)benzofuran/6-APB) has been 
reported [29].  
Overall, these new psychedelic phenethylamine derivatives’ psychoactive effects have 
been suggested to be dose-dependent, ranging from mere stimulant effect at lower doses 
to hallucinogenic and entactogenic effects at higher doses. Being selective 
noradrenaline/dopamine reuptake inhibitors as well, these stimulants produce euphoria, 
talkativeness, disinhibition, increased locomotor activity, alertness and sexual arousal. 
Their intake may be associated with loss of appetite, tachycardia, anxiety, nausea, 
headache, dizziness, skin irritation, and hangover effects. Intoxications symptoms 
include: hypertension, vomiting, hyperthermia, convulsions, respiratory deficits, liver, 
and kidney failure and death in case of overdose [5; 27; 29]. Psychotic symptoms, 
accompanied by dissociation and hallucinations, and intense psychedelic experiences 
are associated with high dosages [27].  
The 2C family is a synthetic psychedelic group of drugs. 2C-I is possibly the most 
popular member of the 2C family, created in the 70s from mescaline. Because of its 
MDMA-like effects, it is commonly used at parties where is known as ‘smiles’ [28••], 
2014). In the USA, 2C-I is currently a Schedule 1 controlled substance [57]. 2C-I’s 
common effects include: muscle spasm, euphoria and raised energy levels, associated 
with paresthesia, and intensification of the sense of touch and skin sensitivity, 
especially at high doses. Moreover, it can cause tachycardia, dehydration, polyuria, 
nausea, and midriasis [28••].   
Recently, several highly active derivatives, the so called ‘NBOMes’, have entered the 
NPS market; they include: 25B-NBOMe (2-(4-bromo-1,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine); 25C-NBOMe ((2-(4-chloro-2,5-dimethoxyphenyl)-N-
[(2-ethoxyphenyl)methyl]ethanamine) aka ‘N-Bomb’/‘Pandora’); and 25I-NBOMe 
((4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine) aka ‘N-bomb’). 
NBOMe compounds act as potent full agonists at the 5-HT2A and 5-HT2C receptors 
(for a comprehensive review, see [28••]). In addition, 25I-NBOMe and 25C-NBOMe 
are pharmacologically active at very low, submilligram doses. Their higher 5-HT2A 
receptor affinity, compared to the 2C-derivatives, explain the frequent associated 
reports of hallucinations and delusions. NBOMe-containing products are usually 
available as tablets, capsules, powder, liquid, spray, and blotters. They are usually taken 
sublingually/orally or via nasal insufflation, with some of them are sold as lysergic acid 
diethylamide (LSD) replacement [28••]. Suzuki and colleagues [58] provided a 
comprehensive literature review of toxicities associated with N-(2-methoxybenzyl)-
2,5-dimethoxy-4-substituted phenethylamines (NBOMe) ingestion. The most common 
adverse reactions may be agitation and aggressiveness, tachycardia, hypertension, and 
seizures.  
Bromo-dragonfly (1-(8-bromobenzo[1,2-b; 4,5-b9]difuran-4-yl)- 2-aminopropane; ‘B-
fly’) is a distant derivative from the core phenethylamine structure, with a potency 
similar to that of LSD but with a far longer duration of effect (1–3 days) and greater 
toxicity [20]. Andreasen and colleagues [59] reported a fatality involving ‘B-fly’.   
Regarding the ‘D family’, Balíková [60] reported both fatalities and near misses after 
ingestion of the psychedelic phenethylamine 2,5-dimethoxy-4-bromoamphetamine 
(DOB).  
 
PCP, ketamine and remaining dissociatives 
Phencyclidine (PCP) and ketamine (‘K’) were developed initially as general 
anaesthetics for human and animal use, but before long they emerged as ‘street’ drugs. 
Other related dissociative analogues entered the recreational drug market relatively 
recently [61], including: the β-keto-arylcyclohexylamines (e.g. methoxetamine, 
deschloroketamine, and 2-fluoro-2-deschloroketamine) molecules [1; 62•];  4-MeO-
PCP [63]; and the 1,2-diarylethylamines (e.g. diphenidine, ephenidine, 
methoxydiphenidine and various analogues such as fluorolintane and N-ethyl-
lanicemine).   
Such drugs act by blocking the NMDA receptor at the PCP binding site as 
uncompetitive antagonists, an action that may induce anaesthetic activity for most of 
these substances at high doses [1; 5; 64-66]. These compounds are known to produce 
dissociative, hallucinogenic and schizophrenomimetic effects [64; 67-69]. The effects 
of these molecules are route and dose-dependent and diverse, generally inducing a 
mind-altering state, with sensory hallucinations, tactile distortions, euphoria, 
derealization and depersonalization [61; 70•]. 
Veterinary clinics are the typical sources of diverted ‘K’, which can be injected, 
snorted, smoked, or administered rectally; the dosage range being 25-300 mg. ‘K’ 
central 5-HT2A agonism [71], NMDA receptor antagonism [72], and high affinity for 
mu/delta/sigma opioid receptors [73] are thought to explain the hallucinogenic effects. 
‘K’ psychoactive effects include near-death experiences (NDEs)/’out-of-body’ 
sensations, such as the ‘K-hole’ [22; 74-76], as well. NDE include sensory deprivation 
[77], extreme joy, sense of travelling in the dark towards bright light, and 
communicating with deceased loved ones [78-79]. Physical adverse effects at times 
associated with NDEs include: hypovolaemia, septic shock, intra-cerebral 
haemorrhage, cerebral infarction, dyspnoea and cardiac arrest [80]. Chronic ketamine 
use can lead to dependence, tolerance, and a withdrawal syndrome; flashbacks typically 
taking the form of perceptual distortions and schizotypal symptoms. Flashbacks may 
persist after use has ceased, and are commonly reported [81]. About one-third of 
chronic ‘K’ users report either intestinal problems (‘K cramps’) [73] or urological 
issues (‘K-bladder’, i.e. abnormal bladder histology, decreased bladder capacity, 
dysuria, haematuria, hydronephrosis, and suprapubic pain) [82]. High ketamine 
consumption levels can cause toxicity leading to cardiovascular and respiratory 
problems. Ketamine-related impaired perception of risk, muscle weakness and 
numbness can cause burns, falls and trauma, including fatal outcomes due to: death 
from hypothermia due to lying outside in winter, drowning, traffic accidents, and being 
a crime victim [76; 83]. Ketamine has a very rapid onset of action i.e. 30 seconds if 
injected intravenously, 5-30 minutes if taken intranasally and 20 minutes if ingested 
orally, with a duration of action of up to three hours [23]. 
Methoxetamine (MXE, ‘Special M’) entered the recreational drug market to avoid 
legislative sanctions through being a structural ‘K’ analogue [22]. MXE can be 
swallowed, taken sublingually, snorted/insufflated, injected or used rectally, with the 
dosage range being 5-100 mg [76; 84-86]. MXE presents with NMDA receptor 
antagonism activity, but also with dopamine-releasing and serotonin transporter 
inhibiting properties [73]. Users report changes in sensory perceptions expressed as 
intensified feelings (e.g. brighter colours and heightened imagery), euphoria, 
empathetic/entactogenic feelings, vivid hallucinations and improved mood [22]. MXE 
consumers often experience long-lasting dissociative effects, i.e. the ‘M-hole’ [19; 22]. 
Intense derealisation, detachment from one’s own body, distorted perceptions of time 
and space, and disorientation are also reported [22]. Undesired effects include low 
mood, aphasia, cognitive impairment, dizziness, confusion, agitation and synaesthesia. 
After acute MXE intravenous injection, tachycardia, hypertension, confusion, agitation, 
stupor, ataxia, mydriasis and nystagmus have been reported [87]. Following chronic 
use, anxiety and suicidal ideation have been a reason of concern [21-22; 57]. Although 
MXE was marketed as ‘bladder friendly’, related pre-clinical studies [88] suggested 
both urological toxicity and unique cerebellar features [89]. Several analytically 
confirmed MXE-related fatalities have been reported [90-91]. 
PCP (‘angel dust’) produces distorted perceptions of sight and sound, dissociation from 
the environment, out-of-body feelings, and hallucinations. Acute symptoms may 
include: memory impairment; altered perception of time; slowness; anxiety; apathy; 
irritability; psychosis; stupor; coma; and violent behaviour. Chronic effects can 
comprise: memory and thinking impairment; mood shifts; anxiety disorders; suicidal 
thoughts; and dependence. PCP intake has been associated with cerebrovascular 
accidents and cardiac arrest [27]; catatonic states [92]; and delirium; the latter having 
led to the discontinuation of its research in the early 1960s [93-94]. Occasional deaths 
have been associated with the use of PCP [95-104]. 
Dextromethorphan 
Dextromethorphan (DXM) is a cough suppressant and opioid derivative, being the 
dextroisomer of the codeine analogue levorphanol. At recommended dosages, DXM is 
considered a safe product. DXM is available as tablets, capsules, lozenges and syrups, 
in a variety of prescription and over-the-counter (OTC) cough and cold remedies, either 
alone or in combination with other ingredients like analgesics, antihistamines and 
expectorants [103]. Nonetheless, since its introduction in the ‘50s, DXM use has been 
abused for high-dosage related hallucinogenic and dissociative effects [5; 104-106]. 
DXM abuse seems to be popular among teens, in being considered a SMART choice, 
which is the acronym for: Stigma (unlike illicit street drugs, DXM purchase and 
assumption has no negative connotation); Money (DXM products are relatively 
inexpensive); Access (easy availability); Risks (low risk perception); and Testing 
(DXM is not detected by drug tests) [103]. DXM use may be associated with a high 
lifetime prevalence of mood, anxiety, and personality disorders [21; 106-107].  
The drug is rapidly absorbed from the gastrointestinal tract, with duration of action 
ranging from 3 to 6 hours [108]. DXM effects depend on its metabolism by cytochrome 
CYP2D6 to dextrorphan and, due to the genetic polymorphisms of CYP2D6, extensive 
metabolizers may be more prone to increase the dosage and suffer from 
neuropsychiatric manifestations [103; 107-109]. 
Similarly to PCP and ketamine, DXM acts as an NMDA receptor antagonist [103; 108; 
110]. Nonetheless, it also shows an a3/b4 nicotinic receptors antagonism; a sigma1 and 
2 opioid receptors agonism; and a serotonin reuptake inhibitory action. Like other 
dissociative agents, dextrorphan is also thought to exert adrenergic effects by inhibiting 
peripheral and central catecholamine reuptake [103; 108]. The long-term use of DXM 
can lead to dependence [103; 111], with the abrupt cessation of the drug resulting in a 
withdrawal syndrome [109].  
DXM characteristics of the intoxication are dose-related. With up to 400mg, 
psychoactive effects include: trance-like euphoria, sense of well-being, profound 
empathy and social relaxation; but also, impairment of motor, cognitive, and perceptual 
functioning, with mild hallucinations, slurred speech, lethargy, ataxia and memory 
impairment. With higher dosages, a proper dissociative state (e.g. ‘robo-ing’, ‘robo-
copping’, or ‘robo-tripping’), is being observed, with ‘out-of-body’ experiences, 
bizarre/idiosyncratic/violent behaviour, paranoid thinking, perceptual distortion, and 
vivid auditory/visual hallucinations [103; 111]. 
Increase in body temperature (which may be a sign of a serotonergic syndrome) [21], 
tachycardia, hypertension, dyspnoea, restlessness, hyperreflexia, and respiratory 
depression may occur [103; 107-109; 111]. Fatal outcomes following the ingestion of 
even massive amounts of DXM alone are rare [112]. DXM intoxications can also 
exhibit signs of toxicity from concurrent compounds, including hepatotoxic effects 
from acetaminophen, anticholinergic effects from diphenhydramine, depressant effects 
from ethanol, and sympathomimetic effects from pseudoephedrine [103; 107-108; 
111]. DXM is often marketed in cough and cold products as ‘dextromethorphan 
hydrobromide’. Thus, there is the possibility of acute/chronic toxicity (‘bromism’) in 
association with substantial DXM ingestion [108; 111].  
The combination of high doses of DXM with other serotonergic drugs, including 
selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, St. John’s Wort, 
and certain antibiotics (e.g., linezolid) may be associated with the development of a 
serotonin syndrome [108].  
 
The possible therapeutic role for psychedelics and dissociatives 
Psilocybin has been shown to uncouple synchronised activity in the posterior cingulate 
cortex and the medial prefrontal cortex. This suppression of regulated patterns of 
activity between different brain areas may characterise the ‘psychedelic state’ [113]. 
There might be a role for psilocybin for the alleviation of anxiety and depression in life-
threatening illness [114-119]. The effect of varying of doses of oral psilocybin (100, 
200, or 300 mg/kg) was tested in a small study on patients suffering from Obsessive 
Compulsive Disorder (OCD) [120], but only one subject had achieved long-term 
remission at the 6-month follow-up. There is some evidence for a possible role of 
psilocybin in the treatment of alcoholism or nicotine addiction [121-122], and 
according to Sewell et al. [123] psilocybin and LSD might also have a role in the 
treatment of cluster headache.  
LSD has been studied as a possible treatment for depression for the last few decades 
[124]. Indeed, 5-HT1A and 5-HT2A receptors are implicated in the pathophysiology of 
dysfunctional emotional biases, with cortical 5-HT2A receptor expression being 
increased in postmortem samples of depressed and suicidal patients [125-127], and 5-
HT2A binding decreased in the hippocampus of depressed patients [128]. Furthermore, 
medication-free depressed patients with high pessimistic attitudes showed increased 5-
HT2A receptor binding in the pre-frontal cortex compared with healthy control subjects 
[129-131]. There are also anecdotal reports of LSD being useful in the treatment of 
OCD [132], with a non-hallucinogenic LSD derivative, BOL-148 (2-bromo-LSD), 
shown to be an effective treatment of cluster headache [133]. 
Animal studies may suggest a possible role for DOI (2,5-Dimethoxy-4-
iodoamphetamine), a nonselective 5-HT2A/2C agonist, as anti-anxiety [134-136].  
Finally, over the last few years, and possibly because of the significant dopaminergic, 
serotonergic and glutamatergic actions of PCP-like compounds, research has focused 
on the possible antidepressant/antisuicidal clinical effects of both ketamine (for a 
thorough review, see [137] and methoxetamine/MXE [138].  
 
Discussion 
The present article offered an updated overview of the clinical and clinical 
pharmacological issues related to some of the most popular NPS categories, e.g. 
dissociatives and hallucinogens. Due to the rapid spread and wide availability of NPS, 
health professionals aim at being fully informed and updated, to be able to adapt their 
response to the potential new challenges that NPS may cause. Moreover, due to the 
difficulty in classifying NPS and their unknown long-term health harms, NPS can be 
considered a global problem,	with	public health, social and safety risks [139].	 As	 a	response,	drug	policies	have	enforced	new	regulatory	approaches	for	NPS, focusing on 
their supply through legislative tools. Furthemore, in many European countries a range 
of effective public health responses, including prevention activities, drug demand and 
harm reduction intervention, have been increasingly implemented , [140]. 
Moreover, the parallel changes in drug scenarios, including the frequent polydrug use, 
the unknown toxicodynamics and toxicokinetics, and unusual presentation to 
emergency departments represent a challenge for psychiatry. In fact, the occurrence of 
both psychosis and remaining psychopathological issues has been related to [5; 28••): 
a) increased central dopamine levels, associated with the intake of most of these 
substances, including novel psychedelic phenethylamines; b) 5-HT2A receptor 
activation, typically reported for all psychedelics and especially for NBOMe 
compounds; latest tryptamine derivatives; and hallucinogenic plants; and c) antagonist 
activity at NMDA receptors, described with all phencyclidine-like dissociatives. 
Although the link between psychedelics, dissociatives, and mental health conditions is 
yet to be fully understood [52], one could argue that, when psychosis does develop and 
persist, this might be the result of a complex interaction between genetic predisposition 
and environment [141••-142].  
From a psychopathological perspective, one could wonder about the similarities and 
differences between schizophrenia; the recreational drug-induced psychosis; the 
dissociative states; and the psychedelic-related psychopathological issues. Clinically, 
the psychotic symptom profiles between cannabis-induced psychotic disorder and acute 
schizophrenia may be very similar; however, cannabis users’ cognition levels are less 
severely affected [141••]. Regarding the use of dissociatives and schizophrenia, there 
are valid and reliable animal models to investigate the neurobiological mechanism of 
psychosis in humans [143]. Furthermore, most recent research has confirmed that both 
occasional ketamine use and ketamine abuse or dependence are associated with 
increased psychotic symptoms [144]. In relation to the severity of the clinically 
observed abnormal beliefs, both patients with schizophrenia and those under the 
influence of ketamine show abnormal function of the right lateral prefrontal cortex or 
lesions with connectivity to this area [145].  
According to De Gregorio et al. [146••], there are similarities between the acute 
hallucinogenic drug-induced states and the acute presentation of endogenous psychoses 
like schizophrenia. Conversely, it is more difficult to understand the chronic 
psychopathological issues observed in psychedelic users. To this respect, Bonhoeffer 
[147] developed a model of ‘exogenous’ psychosis that might help to understand what 
happens during and after the intake of psychedelic substances. This proposed model, 
known as ‘lysergic psychoma’, is described by the subjects as an external body, a sort 
of a ‘tumour/mass’, perceived to be persistently ‘located’ in the mind/ the brain after 
the use of psychedelics. Different from the pervasive schizophrenic experience, this 
may leave unaffected the remaining higher functions, including cognition and mood. In 
other words, the lysergic psychoma is conceptualized as a psychopathological 
experience in which the thinking Ego is still able to acknowledge and ‘contain’ the 
abnormal features (for a thorough review, see [148]).   
Further reported reactions post-psychedelic treatment replicate or mimic the psychotic 
state, as is the case of the hallucinogen-persisting perception disorder (HPPD; replacing 
the term ‘flashbacks’). HPPD includes afterimages, perception of movement in 
peripheral visual fields, blurring of small patterns, halo effects, and macro- and 
micropsia long after the drug has been used [13]. The main characteristic of these 
perceptual disturbances is that they profoundly affect a person’s inner processes and 
the perception of the surrounding world, causing distress or impairment in their 
everyday life [4•]. These perceptual disturbances may be continuous or only occasional, 
and the only certain cause for HPPD is prior use of hallucinogens [4•; 26•; 149].  
 
Psychedelics and dissociatives are being studied as well as potential treatment for 
certain psychiatric conditions, mainly treatment-resistant depression, anxiety and 
addiction disorders [150• -151]. Although it is still unclear if the psychedelic state is 
necessary for their therapeutic effects [141••], it has been suggested that both the 
identification of non-psychedelic compounds with similar serotonergic and 
glutamatergic receptor affinities as psychedelics, as would the identification of non-
psychedelic analogues capable of promoting plasticity in the prefrontal cortex [141••; 
146••) would constitute an important area for future research. 
 
Treatment and management issues  
Consumers of psychedelic and dissociate NPS may present to the Accident and 
Emergency Departments without providing vital information about the substances(s) 
ingested. Furthermore, standard drug tests will likely show negative results [2; 20]. It 
is possible that those patients with less severe symptoms may simply need reassurance, 
support, and monitoring. However, a medication may frequently be needed, e.g. to 
focus on decreasing levels of both self/outward-directed aggression and agitation. Due 
to the complex/unknown pharmacology of the substances arguably ingested, 
benzodiazepines may be the agents of choice, although this may be difficult with those 
intoxicated with alcohol. Where patients cannot be controlled with benzodiazepines 
alone, propofol and/or antipsychotics may be considered, although drugs such as 
haloperidol, olanzapine, or ziprasidone can lower seizure thresholds, limiting the levels 
of heat dissipation and contribute to dysrhythmias (for a full review, see [152••]). 
Hyperthermia, typically associated with phenethylamine psychedelics, needs to be 
evaluated and treated aggressively, and this typically involves cooling measures and 
i.v. fluid administration for rhabdomyolysis concern [28••]. The intake of serotonergic 
drugs (e.g. phenethylamines, hallucinogens, NBOMe compounds, etc.) may be 
associated with the occurrence of the serotonin syndrome, to be managed using both 
benzodiazepines and cyproheptadine [28••].   
 
Conclusions and recommendations 
The online market of novel psychoactive substances is unfortunately developing far 
more rapidly than academic research. Apart from traditional webstores easily accessible 
by users, cryptomarkets have been recently developed. They are anonymous 
marketplaces operating on the so-called darknet, and accessible only via specially 
configured browsers [153]. Vulnerable subjects, including both children/adolescents 
and psychiatric patients, may be exposed to a plethora of ‘pro drug’ web pages, which 
provide direct drug purchase opportunities and/or drug information (e.g., description of 
the drug effects, dose, chemistry and intake experiences; [16]). Unfortunately, 
clinicians are not always aware of the type, effects and psychopathological risks related 
to NPS [154].  
The onset of psychiatric symptoms after the use of these potent and highly rewarding 
drugs is extremely common, especially following repeated use. These episodes, 
sometimes characterized by significant psychotic features, are often self-limited and 
reversible; however, when the use is frequent, persistent, and at high dosages, the onset 
of full and long-lasting psychiatric disorders can be observed [148]. More clinical 
studies are needed to clarify these aspects and the importance of toxic psychosis and 
the complex link between NPS and psychiatric illnesses.  
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